Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Three Way Takeover Battle: Teva plans raising Mylan bid to $43 billion – report

Last week Teva CEO, Erez Vigodman said, “If the Mylan Pharmaceuticals shareholders support the acquisition of Perrigo, Teva will abandon its bid for Mylan.”

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 billion, $86 to $88 a share, as soon as this week, Financial Times report. Mylan had a market value of about $34.4 billion as of last week’s close.

In April, Mylan rejected an offer which valued it at $82 a share, or $40 billion.

“Bloomberg” added that Mylan is planning to hold a shareholder meeting this summer to vote on its Perrigo proposal, and an offer from Teva would pose an alternative for proxy firms advising Mylan shareholders.

Teva’s initial offer in April was contingent on Mylan dropping its bid for Perrigo. Mylan instead raised its offer for the Dublin-based company to $32.7 billion, its third proposal to be rebuffed.

Last week Teva CEO, Erez Vigodman said, “If the Mylan Pharmaceuticals shareholders support the acquisition of Perrigo, Teva will abandon its bid for Mylan.”

 

 

Erez Vigodman- TEVA

“Size is important in the industry, but it isn’t everything. It’s important

to be better. You have to make acquisitions that will suit the company’s

strategic direction and contribute to More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed

first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced

on Friday that it has completed the purchase of a 4.61% More…

Teva CEO Erez Vigodman

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals

Industries Ltd.’s patent for its top-selling multiple sclerosis treatment

Copaxone is invalid. A Teva spokeswoman said that the company is “committed More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) continues

to accumulate shares in takeover target Mylan (MYL), even as Mylan’s largest

shareholder, Abbott Labs (NYSE: ABT), announced its More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

Will drug company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)

succeed in its attempted hostile takeover of rival Mylan (MYL), or will it be Mylan

that succeeds in its own hostile takeover More…

L-R Robert-J-Coury-1-Mylan- Teva Erez Vinograd and Yitzhak Peterburg

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) issued a new open

letter on Monday, signed by both the Teva Chairman Yitzhak Peterburgand and

Teva’s CEO Erez Vigodman, addressed to Robert More…

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement